CTNM

Contineum Therapeutics, Inc. Class A Common Stock

CTNM.US contineum-tx.com + Research + Basket
CIK 0001855175
Employees 51
Phone 858 333 5280
Fiscal year end December
IPO Apr 05, 2024
Address 3565 General Atomics Court, San Diego, CA, United States, 92121
9.10
+0.11 (+1.22%)
USD · NASDAQ
52-week range
6.73
17.79
Trading at 21% of the 52-week range
Market Cap
338.21M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
6.37
Div. Yield
N/A
% Institutions
98.57%
% Insiders
0.069%

1 Year

-19.8%

3 Year

-43.8%

10 Year

-43.8%
Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Actions

Add an action for CTNM.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Carmine N. Stengone MBA, MS President, CEO & Director 1976
Mr. Peter T. Slover CPA Chief Financial Officer 1975
Dr. Timothy R. Watkins M.D., M.Sc. Chief Medical Officer & Head of Development 1974
Ms. Morgan Paulsen Senior Manager of Accounting NA
Dr. Daniel S. Lorrain Ph.D. Chief Science Officer 1969
Mr. Steve E. Kunszabo Senior Director of Investor Relations & Corporate Communications NA
Mr. John S. Healy General Counsel & Corporate Secretary 1972
Mr. Austin Chen Ph.D. Senior VP & Head of Research NA
Ms. Julie S. Iwashita Senior Vice President of Clinical Operations NA
Ms. Kristina Haeckl Rac Senior Vice President of Regulatory Affairs NA

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Suvretta Capital Management, LLC 2.84M Jun 30, 2026 7.55% $0.85 0.00%
HHG PLC 2.73M Mar 31, 2026 7.27% $0.02 11.67%
Jupiter Topco LLC 2.73M Jun 30, 2026 7.27% $0.02 0.00%
BlackRock Inc 2.06M Jun 30, 2026 5.49% $0.00 208.52%
Johnson & Johnson 1.98M Jun 30, 2026 5.26% $4.06 0.00%
Franklin Templeton Inc 1.84M Jun 30, 2026 4.89% $0.01 0.00%
Balyasny Asset Management LLC 1.52M Jun 30, 2026 4.05% $0.03 -9.66%
Vanguard Capital Management, LLC 1.32M Jun 30, 2026 3.51% $0.00 8.83%
Perceptive Advisors LLC 1.26M Jun 30, 2026 3.34% $0.31 0.00%
FMR Inc 1.04M Jun 30, 2026 2.76% $0.00 27.64%
Millennium Management LLC 931.71K Jun 30, 2026 2.48% $0.01 -39.32%
Great Point Partners LLC 921.48K Jun 30, 2026 2.45% $2.85 15.16%
Longaeva Partners L.P. 812.76K Jun 30, 2026 2.16% $0.29 11.02%
Ikarian Capital, LLC 807.87K Jun 30, 2026 2.15% $1.43 0.00%
Sectoral Asset Management Inc 727.59K Jun 30, 2026 1.93% $8.32 0.00%
Geode Capital Management, LLC 693.19K Jun 30, 2026 1.84% $0.00 145.78%
Hillhouse Capital Advisors, Ltd. 669.34K Jun 30, 2026 1.78% $1.32 0.00%
Red Tree Management, LLC 638.16K Sep 30, 2026 1.70% $7.34 0.00%
Versant Venture Management LLC 542.63K Jun 30, 2026 1.44% $5.47 0.00%
The Goldman Sachs Group Inc 497.26K Jun 30, 2026 1.32% $0.00 61.92%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Franklin Biotechnology Discv A(acc)USD 1.10M 2.93% ▲ 0.00% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 982.26K 2.61% ▲ 0.00% Sep 30, 2026
3 iShares Russell 2000 ETF 717.29K 1.91% ▼ 1.14% Sep 30, 2026
4 Franklin Biotechnology Discovery A 601.16K 1.60% ▲ 0.00% Sep 30, 2026
5 Fidelity Select Health Care 450.00K 1.20% ▲ 0.00% Aug 31, 2026
6 Fidelity Small Cap Index 294.82K 0.78% ▲ 1.17% Jul 31, 2026
7 Fidelity Advisor Health Care I 280.00K 0.74% ▲ 0.00% Aug 31, 2026
8 iShares Russell 2000 Value ETF 256.27K 0.68% ▲ 0.15% Sep 30, 2026
9 State Street® SPDR® S&P® PhrmctlsETF 252.95K 0.67% ▼ 1.23% Sep 30, 2026
10 iShares Biotechnology ETF 233.13K 0.62% ▼ 0.75% Sep 30, 2026

Financial Highlights

▼
Market Cap: $338.21M
EBITDA: $-66.00M
Book Value: $6.37
Earnings/Share: $-1.91
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -19.15%
ROE (TTM): -28.00%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $77.01M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 32.96M
Shares Float: 27.70M
% Insiders: 0.069%
% Institutions: 98.57%
Short % Float: 9.36%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-323.00K
Gross Profit
subtotal
$-323.00K
SG&A
adjust
$-16.54M
R&D
adjust
$-51.52M
Operating Income
subtotal
$-68.06M
Other / Non-Operating Items
adjust
$8.08M
Net Income
subtotal
$-59.98M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CTNM.US!